UPDATE: Barrington Research Initiates TranS1 at Outperform on Growth Outlook
Barrington Research initiated coverage on TranS1 (NASDAQ: TSON) with an Outperform rating and a $4 price target.
Barrington Research said, "We estimate that the minimally invasive spinal fusion market is less than 30% of the total market and over the next few years, we expect the percentage of minimally invasive procedures to approach 60%. We estimate the potential lumbar spinal fusion market is well in excess of $1 billion. We believe TSON has the least invasive approach for the treatment of S1/L5/L4 and in our opinion, TSON will be a market leader of this segment as the company convinces the masses, doctor by doctor."
TranS1 closed at $2.42 on Friday.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.